See every side of every news story
Published loading...Updated

Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth - Stryker (NYSE:SYK)

Summary by Benzinga
Wall Street analysts rerated Stryker Corp (NYSE:SYK) Wednesday after the company’s fourth-quarter print. Stryker reported quarterly earnings of $4.01 per share, which beat the analyst consensus estimate of $3.87. The company reported quarterly sales of $6.44 billion, up by 10.7%, which beat the analyst consensus estimate of $6.36 billion. Also Read: Nasdaq Touts 10% Revenue Growth In Q4, Sets 2025 Expense And Tax Guidance Several analysts rerate…

5 Articles

All
Left
Center
3
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Globe Newswire broke the news in on Tuesday, January 28, 2025.
Sources are mostly out of (0)